# Peptide-drug & small-molecule-drug conjugates

Source: https://nuclide.cc/technologies/peptide-drug-conjugate/  
Nuclide record `peptide-drug-conjugate` (Technology). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Like an ADC but with a small targeting peptide instead of an antibody, so it penetrates tumours faster and is cheaper to make.

## Summary

Peptide-drug conjugates replace the antibody of an ADC with a short or bicyclic peptide that binds the target, giving rapid tumour penetration and renal clearance, with a short half-life that reduces systemic exposure and cheaper synthesis. Examples include melflufen (Pepaxto, withdrawn in the US), lutetium radioligands (technically peptide-radionuclide conjugates), and clinical-stage PDCs such as BT8009 zelenectide pevedotin, a Nectin-4 Bicycle toxin conjugate, and CBX-12, an exatecan-SMDC. Bicycle's zelenectide pevedotin is in phase 2/3 in urothelial cancer. The same short half-life that limits toxicity also limits tumour exposure, and renal toxicity is a class concern. The simple version is an ADC with a small peptide as the address label, faster to penetrate tumours and cheaper to make.

## Fields

- Kind: Technology
- Status: approved
- Last checked: 2026-09-04
- Principle: Short peptide or bicyclic peptide binds the target; short half-life reduces systemic exposure.
- Strengths: Rapid penetration, renal clearance; Cheaper synthesis
- Limitations: Short half-life limits tumour exposure; Renal toxicity

## Sources

- Cooper et al., Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (Chemical Society Reviews 2021): https://doi.org/10.1039/D0CS00556H

## Connected records

- targets: [Nectin-4](https://nuclide.cc/targets/nectin4/), [Sortilin (SORT1)](https://nuclide.cc/targets/sortilin/)
- opportunities: [A liver-cleared Nectin-4 tracer for urothelial cancer](https://nuclide.cc/opportunities/opp-nectin4-imaging-urothelial/), [GRPR imaging when the PSMA scan is negative](https://nuclide.cc/opportunities/opp-grpr-psma-negative-prostate/)
- fronts: [Radioligand therapy](https://nuclide.cc/fronts/f-radioligand-therapy/)

---
JSON: https://nuclide.cc/api/v1/entities/peptide-drug-conjugate.json